Original Article

Clinical characteristics of septo-optic dysplasia accompanied by congenital central hypothyroidism in Japan

Keisuke Nagasaki1, 15, Takuo Kubota2, 15, Hironori Kobayashi3, 15, Hirotake Sawada4, 15, Chikahiko Numakura5, 15, Shohei Harada6, 15, Kei Takasawa7, 15, Kanshi Minamitani8, 15, Tomohiro Ishii9, 15, Satoshi Okada10, 15, Hotaka Kamasaki11, 15, Shigetaka Sugihara12, 15, Masanori Adachi13, 15, and Toshihiro Tajima14, 15

1Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
2Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
3Department of Pediatrics, Shimane University Faculty of Medicine, Shimane, Japan
4Department of Reproductive and Developmental Medicine, University of Miyazaki, Miyazaki, Japan
5Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
6Faculty of Child Studies, Seitoku University, Chiba, Japan
7Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan
8Department of Pediatrics, Teikyo University Chiba Medical Center, Chiba, Japan
9Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
10Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan
11Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
12Department of Pediatrics, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
13Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama, Japan
14Department of Pediatrics, Jichi Children's Medical Center Tochigi, Tochigi, Japan
15The Committee on Mass Screening of the Japanese Society for Pediatric Endocrinology

Abstract. Septo-optic dysplasia (SOD) is a congenital anomaly in which agenesis of the septum pellucidum and optic nerve hypoplasia are accompanied by hypopituitarism. Typically, the symptoms develop in 3 organs, the brain, eyes, and pituitary, and approximately one third of the patients present with all of the three cardinal features. The diagnostic criteria for SOD were established in Japan in 2015. The purpose of this study is to review clinical features regarding SOD patients with hypopituitarism in Japan. In this study, 21 patients with SOD were identified by a questionnaire survey for congenital central hypothyroidism. All 3 symptoms of SOD, agenesis of the septum pellucidum, optic nerve hypoplasia, and endocrine abnormalities, were noted in 8 of the 21 patients. Various combinations of pituitary hormone deficiencies were observed in patients with SOD, although SOD
is a rare, heterogeneous, and phenotypically variable disorder, some patients develop hypoglycemia and convulsions after birth, and early intervention with hormone replacement is necessary in severe cases. In addition, 14 cases were complicated by both developmental delay and epilepsy, and 16 cases involved eye abnormalities. Therefore, in addition to an early endocrinological diagnosis and hormone replacement, consultation with both pediatric neurologists and pediatric ophthalmologists is necessary.

Key words: septo-optic dysplasia, combined pituitary hormone deficiency, optic nerve hypoplasia, agenesis of the septum pellucidum, congenital central hypothyroidism

Introduction

Septo-optic dysplasia (SOD) is a congenital anomaly in which agenesis of the septum pellucidum and optic nerve hypoplasia are accompanied by hypopituitarism. According to a survey conducted in England, the annual incidence of SOD was estimated to be 1 in 10,000 births or lower, and the male : female ratio was 1:1 (1–3), however the frequency of occurrence in Japan is not known. The etiology of SOD is unclear in several cases, although an association with childbearing at a young age and drug addiction of pregnant women has been suggested. Although the largely sporadic occurrence of SOD remains unexplained, viral infections and other environmental causes have been implicated (1). Gene mutations associated with SOD, in transcriptional factors involved in the development of the pituitary, such as HESX1, SOX2, and OTX2 have been identified, although such mutations are very rare (1–3).

Typically, patients with SOD develop symptoms in 3 organs, the brain, eyes, and pituitary, and approximately one third of the patients present with all the three cardinal features of the disease. The disease is difficult to manage owing to visual disturbances, epileptic seizures, and cerebral palsy; the intellectual disturbances vary from normal to severe (1–4). Dysfunction of both, the anterior and posterior pituitary hormones, occurs but the severity and combinations of deficiency of the hormones vary among the patients (1–3). Early diagnosis of TSH, GH, ACTH, and AVP deficiencies and early treatment with hormone replacement therapy are very important (1, 2, 5).

A nationwide questionnaire survey was carried out among the councilors of the Japanese Society for Pediatric Endocrinology to investigate the current state of treatment for congenital central hypothyroidism (CCH) throughout Japan. A total of 21 patients with SOD were identified. We report here on the endocrine characteristics, neurologic manifestations, eye symptoms, and MRI findings of the brain and pituitary of these patients with SOD. The purpose of this study is to review clinical features regarding SOD patients with hypopituitarism in Japan.

Methods

SOD was diagnosed according to the guidelines of the Japan Intractable Diseases Information Center septo-optic dysplasia/De Morsier syndrome (specified intractable disease 134) (6) (Table 1). The subjects were patients who were diagnosed with CCH between April 2004 and March 2014. An epidemiological survey was conducted among pediatric endocrinologists (councilors of the Japanese Society for Pediatric Endocrinology) throughout Japan who were likely to be involved in the management of patients with CCH. As a primary survey, 191 councilors of
Table 1  Diagnostic criteria of septo-optic dysplasia

Cases meeting at least 2 of the 3 abnormalities, as shown below, are diagnosed as septo-optic dysplasia.

| 1) Agenesis of the septum pellucidum |
| 2) Endocrine abnormalities (described below) |
| 3) Optic nerve hypoplasia (unilateral or bilateral) |

[Since endocrine abnormalities are not observed in the early phase in many of the cases, it is necessary to screen for the development of endocrine abnormalities up to adolescence, until either 1) or 3) is observed]

Endocrine abnormalities (Endocrine-related diagnostic criteria)

One or more symptoms of hypopituitarism as shown below are observed.

(A: Clinical symptoms or B: endocrine test finding)

A Clinical symptoms

1. Short stature (note 1)
2. Symptomatic hypoglycemia (note 2)
3. Neonatal respiratory disturbance (note 2)
4. Protracted jaundice (note 2)
5. Micropenis/undescended testicle
6. Delayed secondary sexual characteristics
7. Polydipsia/polyuria (note 3)
8. Precocious puberty (note 4)

Note 1: Short stature with GH deficiency is to be diagnosed based on the guidance for diagnosis prepared by the Research on Measures for Intractable Diseases.

Note 2: It is a nonspecific symptom in the neonatal period, but it may develop due to pituitary hormone deficiency.

Note 3: Vasopressin deficiency (diabetes insipidus) is to be diagnosed based on the guidance for diagnosis prepared by the Research on Measures for Intractable Diseases.

Note 4: Central precocious puberty is to be diagnosed based on the guidance for diagnosis prepared by the Research on Measures for Intractable Diseases.

B Endocrine test

Complications with one or more of the conditions, shown below, are observed.

1. GH deficiency (note 5)
2. TSH deficiency (note 5)
3. gonadotropin deficiency (LH, FSH) (note 5)
4. ACTH deficiency (note 5)
5. AVP deficiency
6. Increased secretion of gonadotropin

Note 5: Deficiency of anterior pituitary hormones is caused by dysfunction both, the pituitary and hypothalamus.

C Imaging findings (reference findings)

1. Hypoplasia of the anterior lobe of the pituitary
2. Either thinning of or non-identifiable pituitary stalk on MRI
3. Hypoplasia of either the posterior lobe of the pituitary or ectopic posterior lobe

the Japanese Society for Pediatric Endocrinology were queried about whether they were treating patients with CCH, including suspected cases, between December 2014 and January 2015. The request for this information was made through an e-mail in association with the Society (primary
survey). The secondary survey form was sent to the institutions identified in the primary survey that reported to treating the particular patients, and clinical information was collected (July 2015–March 2016). The details of the methods and subjects were previously reported (7).

This survey was performed after approval by the Ethics Committee of Niigata University School of Medicine, and an outline of the study was published on the homepage (http://jspe.umin.jp/medical/research/CongenitalCH/index.html).

Results

The age, specific findings leading to the SOD diagnosis, endocrine-related findings, MRIs findings of the pituitary and brain, ophthalmologic findings, neurologic manifestations, and genetic abnormalities of the study subjects are summarized in Table 2.

Of the 21 patients with SOD (16 men and 5 women), 8 met the diagnostic criteria with respect to the three main symptoms: agenesis of the septum pellucidum, eye abnormalities, and endocrine disorders, 9 patients developed endocrine and eye abnormalities, and 4 patients developed endocrine disorder and agenesis of the septum pellucidum.

The age at the time of diagnosis ranged from after birth to 2 yr and 3 mo. The findings that led to the diagnosis were neonatal hypoglycemia, convulsions, protracted jaundice, polyuria immediately after birth, and growth disturbances. The disease was diagnosed upon finding the absence of pursuit eye movements in 2 patients. The disease was identified on neonatal mass screening to detect CCH, by measuring free thyroxine (FT4), in 2 patients. The thyroid function tests at initial diagnosis were FT4 0.66 ng/dl / TSH 4.8 µU/ml at the age of 20 d and FT4 0.11 ng/dl / TSH 1.2 µU/ml at the age of 9 d. Both of them are before attendance at school, and the degree of the development is unknown.

As the survey was focus on CCH, TSH deficiency was observed in all the patients. Other than TSH, the anterior pituitary function was evaluated in 20 patients, and GH, ACTH, LH/FSH, and AVP deficiencies were noted in 17, 16, 7, and 6 patients, respectively. Dysplasia of the pituitary was noted in 20 of the 21 patients. In Case 17, the anterior lobe of the pituitary was normal, but the posterior lobe could not be identified on MRI. In Case 16, TSH deficiency and diabetes insipidus were observed, and the anterior lobe of the pituitary was normal, but the posterior lobe was hypoplastic.

Developmental delay and epilepsy were observed in 15 and 4 patients, respectively. Eye symptoms were noted in 16 patients. Unilateral optic nerve hypoplasia and microphthalmia were observed in 3 patients. Anophthalmia was noted in 2 patients.

Mutations were identified in SOX2 and OTX2 genes in the patients with anophthalmia, and a WDR11 gene abnormality was identified in a patient with right microphthalmia.

Discussion

The endocrine-related characteristics of SOD were identified, and it was found that specific hormone deficiencies varied among the cases. Symptoms developed within one week after birth in 6 of the 21 patients, and diabetes insipidus was found in 1 of these patients. The symptoms were hypoglycemia and hypothermia in the other 5 patients, and GH and ACTH deficiencies were present in addition to TSH deficiency. These are serious complications of congenital hypopituitarism (5, 8) that correlate with the findings that some cases of SOD develop severe hypopituitarism early after birth. Hormone replacement to treat hormone deficiencies is very important to improve the morbidity of patients with SOD, for which early endocrinological diagnosis is important.

The etiology of SOD is unclear, as described above, and reportedly, genetic and environmental factors are involved (1–3). SOD may be diagnosed
Table 2  Characteristics of patients with SOD

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age at diagnosis</th>
<th>First symptoms</th>
<th>Pituitary hormone deficiency</th>
<th>Pituitary MRI</th>
<th>Brain MRI</th>
<th>Eye</th>
<th>Neurological defect</th>
<th>Genetic defect</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>2 mo</td>
<td>Icterus</td>
<td>GH/TSH/ACTH/AVP</td>
<td>EPP</td>
<td>–</td>
<td>ONH</td>
<td>Delay</td>
<td>SOX2</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>3 d</td>
<td>HT, HG</td>
<td>GH/TSH/ACTH</td>
<td>HAP</td>
<td>–</td>
<td>ONH</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>5 mo</td>
<td>HG, Sei</td>
<td>GH/TSH/ACTH/LH/FSH/AVP</td>
<td>HAP</td>
<td>DCC</td>
<td>–</td>
<td>Delay</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>20 d</td>
<td>MS</td>
<td>GH/TSH</td>
<td>No visible stalk</td>
<td>DSP</td>
<td>ONH</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>1 yr 11 mo</td>
<td>HG, Sei</td>
<td>GH/TSH/ACTH/AVP</td>
<td>HAP, EPP</td>
<td>DCC, DSP</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>5 mo</td>
<td>No eye contact</td>
<td>GH/TSH/ACTH</td>
<td>EPP</td>
<td>DSP</td>
<td>ONH</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>6 d</td>
<td>HT, HG</td>
<td>GH/TSH/ACTH/LH/FSH</td>
<td>No visible stalk, no PP</td>
<td>DSP</td>
<td>Lt-ONH</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>5 mo</td>
<td>Failure to thrive</td>
<td>TSH/ACTH</td>
<td>HAP, no PP</td>
<td>DCC, DSP</td>
<td>–</td>
<td>Delay</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>3 mo</td>
<td>No eye contact</td>
<td>GH/TSH</td>
<td>HAP, EPP, no visible stalk</td>
<td>DSP</td>
<td>Rt-ONH</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>2 yr 3 mo</td>
<td>Sei</td>
<td>GH/TSH/ACTH</td>
<td>HAP, no PP</td>
<td>DSP</td>
<td>–</td>
<td>Delay</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>1 mo</td>
<td>HG, Failure to thrive</td>
<td>GH/TSH/ACTH</td>
<td>HAP, EPP</td>
<td>–</td>
<td>ONH</td>
<td>Delay</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>1 d</td>
<td>HG, Sei</td>
<td>TSH/ACTH</td>
<td>HAP, EPP</td>
<td>DSP</td>
<td>ONH</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>1 d</td>
<td>HG, not doing well</td>
<td>GH/TSH/ACTH/LH/FSH/AVP</td>
<td>HAP, no PP</td>
<td>DSP</td>
<td>ONH</td>
<td>Delay, Epi</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>3 yr</td>
<td>Short stature</td>
<td>GH/TSH</td>
<td>No visible stalk, EPP</td>
<td>DSP</td>
<td>–</td>
<td>Delay</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>9 mo</td>
<td>Failure to thrive, developmental delay</td>
<td>GH/TSH/LH/FSH</td>
<td>HAP, EPP</td>
<td>–</td>
<td>Anoph</td>
<td>ONH</td>
<td>Delay</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>0 d</td>
<td>Polyuria</td>
<td>TSH/AVP</td>
<td>Small PP</td>
<td>DCC</td>
<td>ONH</td>
<td>Delay, Epi</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>1 d</td>
<td>HG, Sei</td>
<td>GH/TSH/ACTH</td>
<td>Normal AP, No PP</td>
<td>DSP</td>
<td>ONH</td>
<td>Delay</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>9 d</td>
<td>MS</td>
<td>GH/TSH/ACTH/LH/FSH</td>
<td>Aplastic AP, No PP</td>
<td>–</td>
<td>Microph</td>
<td>ONH</td>
<td>Delay</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>2 yr 2 mo</td>
<td>Short stature</td>
<td>GH/TSH/ACTH/LH/FSH/AVP</td>
<td>HAP, EPP</td>
<td>–</td>
<td>ONH</td>
<td>Delay, Epi</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>1 yr 9 mo</td>
<td>Short stature</td>
<td>GH/TSH/ACTH/LH/FSH</td>
<td>HAP, EPP, no visible stalk</td>
<td>–</td>
<td>Anoph</td>
<td>Delay</td>
<td>OTX2</td>
</tr>
<tr>
<td>21</td>
<td>M</td>
<td>2 yr</td>
<td>HG</td>
<td>GH/TSH/ACTH</td>
<td>HAP</td>
<td>–</td>
<td>Rt-Microph</td>
<td>Delay</td>
<td>WDR11</td>
</tr>
</tbody>
</table>

1 HT, hypothermia, 2 HG, hypoglycemia, 3 Sei, seizure, 4 MS, mass screening, 5 EPP, ectopic posterior pituitary, 6 HAP, hypoplasia of anterior pituitary, 7 PP, posterior pituitary, 8 DCC, defect of corpus callosum, 9 DSP, defect of septum pellucidum, 10 ONH, optic nerve hypoplasia, 11 Anoph, anophthalmia, 12 Microph, microphthalmia, 13 Epi, epilepsy.
when at least 2 of the 3 main symptoms are observed. Accordingly, very heterogeneous diseases may be included in SOD, and the causes are also diverse; HESX1, SOX2, SOX3, and OTX2 gene aberrations have been reported (1, 9–11), although these genetic abnormalities are rare, and development of SOD due to a KAL1 gene aberration in Kallmann syndrome has recently been reported (12). In the present survey, a SOX2 gene deletion and an OTX2 gene mutation were present in the patients with anophthalmia. A SOX2 gene aberration was initially reported as a cause of anophthalmia and microphthalmia, but it was subsequently found to induce a wide range of symptoms, such as hypogonadotropic hypogonadism, pituitary hypoplasia, combined pituitary hormone deficiency (CPHD), morphological abnormality of the hippocampus, agenesis of the septum pellucidum, and sensorineural deafness (1, 10). An OTX2 gene aberration also manifests as anophthalmia and microphthalmia, but development of pituitary hypoplasia and CPHD have also been reported, which may cause SOD (1, 5, 11). In addition, a WDR11 mutation was identified in 1 patient with microphthalmia. A WDR11 aberration, particularly 4 missense mutations, has been identified as a cause of hypogonadotropic hypogonadism, similar to a SOX2 aberration (13). At present, the association of these mutations with CPHD, pituitary formation, eye development, and the optic nerve is unclear.

There are several limitations of this study. Since the focus was on SOD in the survey of endocrine-related symptoms, particularly CCH, the endocrine-related pathology of patients without TSH deficiency was unclear. Moreover, the pathology of patients with agenesis of the septum pellucidum and eye symptoms without endocrine-related symptoms was unclear. The clinical characteristics of SOD patients will be further clarified with the registration of intractable disease patients with SOD in the future. Although there are several limitations, the present study helps to understand the endocrine-related characteristics and severity of the disease based on the analysis of a reasonable number (21) of SOD cases.

**Conclusions**

Various combinations of pituitary hormone deficiencies occur in patients with SOD.

Although SOD is a rare, heterogeneous and phenotypically variable disorder, some patients develop hypoglycemia and convulsions after birth, and early intervention with hormone replacement is necessary for the severe cases.

Since the disease is accompanied by serious neurologic manifestations and eye abnormalities, communication with pediatric neurologists and pediatric ophthalmologists is necessary.

**Conflicts of interest:** The authors declare no conflict of interest.

**Acknowledgments**

We are grateful to Dr. Mitsuhiro Kato, Department of Pediatrics Showa University School of Medicine, Dr. Miho Sato, Department of Ophthalmology Hamamatsu University School of Medicine, and Dr. Takashi Kawamura, Kyoto University Health Service, the representatives of Study Group for survey of the actual state of septo-optic dysplasia and preparation of diagnostic criteria·severity classification in Research project for Intractable Disease Measures, for giving us valuable advice related to this study.

This study was partially supported by the Health and Labour Sciences Research Grants, Research on Intractable Diseases, Research Committee on Septo-Optic Dysplasia of the Ministry of Health, Labour, and Welfare, Japan (H27-7).
References